• Publications
  • Influence
Stroke: Working Toward a Prioritized World Agenda
TLDR
The Synergium was to devise and prioritize new ways of accelerating progress in reducing the risks, effects, and consequences of stroke by using a “Brain Health” concept that enables promotion of preventive measures. Expand
Predictors and Biomarkers of Treatment Gains in a Clinical Stroke Trial Targeting the Lower Extremity
TLDR
A multimodal model incorporating behavioral and fMRI measures best predicted treatment-induced changes in gait velocity in a clinical trial setting, and results suggest potential use of f MRI measures as biomarkers of treatment gains. Expand
Randomized, Placebo-Controlled, Double-Blind Study of Ropinirole in Chronic Stroke
TLDR
Ropinirole+PT was generally safe and well tolerated, including no drug-related serious adverse events, and significant gains were found over time for gait velocity and for most secondary end points, however, gains did not differ by treatment assignment. Expand
Proof-of-Concept Randomized Trial of the Monoclonal Antibody GSK249320 Versus Placebo in Stroke Patients
TLDR
GSK249320, within 72 hours of stroke, demonstrated no improvement on gait velocity compared with placebo, findings potentially useful to future studies aiming to use a monoclonal antibody to modify activity in specific biological pathways to improve recovery from stroke. Expand
Methods for an International Randomized Clinical Trial to Investigate the Effect of Gsk249320 on Motor Cortex Neurophysiology using Transcranial Magnetic Stimulation in Survivors of Stroke
TLDR
Standardized methods of applying TMS motor cortex assessments in an international clinical trial of a pharmacological intervention for stroke patients, which was conducted at 15 centers in three countries, are described. Expand
Stroke: Working toward a Prioritized World Agenda
TLDR
The Synergium was to devise and prioritize new ways of accelerating progress in reducing the risks, effects, and consequences of stroke by using a ‘Brain Health’ concept that enables promotion of preventive measures. Expand
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Repeat Doses of GSK249320 in Patients With Stroke
TLDR
Modality-specific end points could be consistently measured in the first few days after stroke, and one of these, gait velocity, demonstrated a trend toward improvement with GSK249320 compared with placebo, suggesting that this first study of a monoclonal antibody to modulate the neurobiology of brain repair after stroke was generally well tolerated. Expand
Safety , Pharmacokinetics , and Pharmacodynamics of Escalating Repeat Doses of GSK 249320 in Patients With Stroke
Rationale: Myelin-associated glycoprotein (MAG) is one of the key proteins known to inhibit neuronal regeneration when released from oligodendrocytes in conditions of neuronal injury, such as stroke.Expand
Ropinirole in the treatment of motor deficits after stroke: A randomized, placebo-controlled, double-blind study
TLDR
This research presents a “robust case study” of the immune system’s response to the presence of infectious disease in eight people over a 12-month period. Expand
Stroke: Working toward a Prioritized World Agenda
TLDR
The aim of the Synergium was to devise and prioritize new ways of accelerating progress in reducing the risks, effects, and consequences of stroke by using a ***‘Brain Health’ concept that enables promotion of preventive measures. Expand
...
1
2
...